TOKYO
The Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) hereby announces procurement of funds totaling ¥11,000 million upon completion of exercise of share acquisition rights with an exercise price adjustment clause issued on April 6, 2018. The funds procured will be used for the following purposes as investments for medium-term growth.
|
Overview of funds procured in the current fiscal year (from February 1, 2018 to January 31, 2019) |
||||||||
| Contracting party | Form of funding | Amount of funds procured | Date of agreement
(or date of approval) |
Use of funds | ||||
|
– |
Equity finance
(share acquisition rights with an exercise price adjustment clause by third-party allotment) |
¥11,000 million |
–
|
|
||||
|
Overview of funds procured in the previous fiscal year (from February 1, 2017 to January 31, 2018) |
||||||||
| Contracting party | Form of funding | Amount of funds procured | Date of agreement (or date of approval) | Use of funds | ||||
| Mitsubishi UFJ Trust and Banking Corporation | Borrowing | ¥900 million | March 2017 |
|
||||
| California Institute for Regenerative Medicine (CIRM) | Grant | $20 million
(¥2,200 million)* |
June 2017 | Phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US | ||||
| Mizuho Bank, Ltd. | Commitment line | ¥1,600 million | August 2017 | Cash in reserve for phase 2 clinical trial for the treatment of chronic motor deficit from TBI in the US and Japan | ||||
| Mitsubishi UFJ Trust and Banking Corporation | Commitment line | ¥500 million | October 2017 | Cash in reserve for phase 2 clinical trial for the treatment of chronic motor deficit from TBI in the US and Japan | ||||
| Total: ¥5,200 million | ||||||||
|
*Exchange rate: $1=¥110 |
||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20180626005683/en/
CONTACT
For more information, contact:
SanBio Co., Ltd.
Masahito
Kumagae, +81-3-6264-3481
Management Administration
